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Abstract
Background: Artemisia campestris L. (Asteraceae) is a medicinal herb traditionally used to treat hypertension and
many other diseases. Hence, this study is aimed to analyze the essential oil of A. campestris L (AcEO) and to
investigate the antiplatelet, antioxidant effects and the mechanisms of its vasorelaxant effect.
Methods: The chemical composition of AcEO was elucidated using GC/MS analysis. Then, the antioxidant effect
was tested on DPPH radical scavenging and on the prevention of β-carotene bleaching. The antiplatelet effect was
performed on the presence of the platelet agonists: thrombin and ADP. The mechanism of action of the vasorelaxant
effect was studied by using the cellular blockers specified to explore the involvement of NO/GC pathway and in the
presence of calcium channels blockers and potassium channels blockers.
Results: AcEO is predominated by the volatiles: spathulenol, ß-eudesmol and p-cymene. The maximal antioxidant effect
was obtained with the dose 2 mg/ml of AcEO. The dose 1 mg/ml of AcEO showed a maximum antiplatelet effect of,
respectively 49.73% ±9.54 and 48.20% ±8.49 on thrombin and ADP. The vasorelaxation seems not to be mediated via
NOS/GC pathway neither via the potassium channels. However, pretreatment with calcium channels blockers attenuated
this effect, suggesting that the vasorelaxation is mediated via inhibition of L-type Ca2+ channels and the activation of
SERCA pumps of reticulum plasma.
Conclusion: This study confirms the antioxidant, antiplatelet and vasorelaxant effects of A.campestris L essential oil.
However, the antihypertensive use of this oil should be further confirmed by the chemical fractionation and subsequent
bio-guided assays.
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Background
A. campestris L. is an Asteraceae plant commonly known
as field wormwood; it is a perennial undershrub (30–
150 cm height), with branched and ascending brownish-
red stems. Leaves are green, the basal are 2–3 pinnatisects,
the upper are simple. Inflorescence is an ovoid, heterogam-
ous yellowish capitulum, with an involucral bracts; ray
flowers are female, pistillate and fertile, while the disk
flowers are sterile, and functionally male [1–3]. In
Morocco, A.campestris L. known as “Allal”, is used as anti-
diabetic [4], to treat digestive, respiratory, metabolic, aller-
gic problems [5, 6] and cutaneous problems [7]. This herb
has many other ethnomedicinal uses like antihypertensive
[8], emmenaguogue [9, 10], and well known for treatment
of liver and kidney disorders [11–13] and as. Previous
pharmacological studies proved that A. campestris L.
possesses antioxidant [14–20], antibacterial, antifungal
[20–25], insecticidal [26–28], antitumor [14, 29–31], anti-
venin [32, 33], hepatoprotective, nephroprotective [34–37]
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and antidiabetic [38, 39] effects. Recently a clinical trial
conducted on volunteers demonstrated that A.campestris
L. enhanced 33.3% to 50% decrease in arterial pressure
among hypertensive smoker patients [40]. In another
study, the administration of A.campestris L. extract in-
duced antihypertensive effect on envenomed hypertensive
rats, and provoked 10% to 30% of hypertension drop, while
the pretreatment with the herb extract prevented the rise
of hypertension [32]. Nevertheless, no in-vitro study has
been elaborated to evaluate the antihypertensive potential
of this plant. In the aim to highlight the importance of
this plant in the cardiovascular therapy, this study was
performed to analyze the essential oil of A. campestris L.
(AcEO) growing in oriental Morocco, to investigate its
vasorelaxant and subsequent mechanism of action and to
determine its antiplatelet and antioxidant effects.
Methods
Chemicals
The following drugs and solvents were used in this study:
(±)-verapamil hydrochloride (Sigma Aldrich, China), (R)-
(-)-phenylephrine hydrochloride [Phe] (Sigma Aldrich,
Germany), 1H-[1, 2, 4] Oxadiazolo[4,3-a]quinoxalin-1-one
[ODQ] (Cayman Chemical, USA), 2, 2-diphenyl-1-picryl-
hydrazyl [DPPH] (Alfa Aesar, Germany), 4-aminopyridine
[4-AP] (Alfa Aesar, Germany), adenosine 5′-diphosphate
[ADP] (Sigma Aldrich, Germany), atropine (Sigma Aldrich,
China), barium chloride dehydrate [BaCl2] (AnalaR
Normapur - VWR International, Belgium), calcium
chloride dehydrate [CaCl2, 2H2O] (Scharlau chemie,
Spain), calmidazolium chloride (Sigma Aldrich, USA),
carbamylcholine chloride [carbachol] (Sigma Aldrich,
USA), citric acid (Farco chemical, Puerto Rico), D(+)-
glucose anhydrous (Sigma Aldrich_Riedel-de Haen,
Germany), gelatin extrapur (HIMEDIA, India), glyben-
clamide (Sigma Aldrich, USA), hydroxocobalamin
hydrochloride (Fluka, USA), indomethacin (Sigma
Aldrich-Fluka, Italy), L-ascorbic acid (Sigma Aldrich,
UK), linoleic acid (Sigma Aldrich, USA), magnesium
sulfate [MgSO4] (Sigma Aldrich, Germany), Nω-Nitro-
L-arginine methyl ester hydrochloride [L-NAME]
(Sigma Aldrich, Switzerland), potassium di-hydrogen
phosphate [KH2PO4] (Panreac, Spain), Rp-8-Bromo-β-
phenyl-1,N2-ethenoguanosine3′,5′-cyclicmonophosphor-
othioate sodium salt [Rp-8-Br-PET-cGMP] (Sigma Al-
drich, Germany), sodium chloride [NaCl] (Sigma
Aldrich_Riedel-de Haen, Denmark), sodium hydrogen
carbonate [NaHCO3] (Farco chemical, Puerto Rico],
potassium chloride [KCl] (Sigma Aldrich_Riedel-de Haen,
Germany), tetraethyl ammonium chloride hydrate [TEA]
(Sigma Aldrich, USA), thapsigargin (Sigma Aldrich,
Israel), thrombin, from bovine plasma (Sigma Aldrich,
USA), trisodium citrate (Acros organics, belgium), Tween
40 (Sigma Aldrich, USA), β-carotene (Sigma Aldrich,
USA). The solvents utilized were: chloroform (Sigma Aldri-
ch_Riedel-de Haen, Germany), diethyl ether (Sigma Aldrich,
Germany), dimethyl sulfoxide [DMSO] (Sigma Aldrich_
Riedel-de Haen, Germany), methanol (Sigma Aldrich,
Germany). All chemicals and solvents used were analytical
grade. The stock solutions of ODQ, thapsigargin and Rp-8-
Br-PET-cGMP were prepared in DMSO whereas indometh-
acin was prepared in 5% (w/v) sodium bicarbonate solution.
All other drugs were dissolved in distilled water.
Plant material
The aerial part of A. campestris L. was collected at
flowering stage in September 2012 in desert region of
Figuig (in South-East of Morocco in the border area with
Algeria). The species was identified by a botanist Pr.
Aatika Mihamou from biology department, and a voucher
specimen was deposited in the herbarium of the Faculty of
Sciences, University Mohamed First (Oujda, Morocco)
under the number HUMPOM-151.
Preparation of A.campestris L. essential oil (AcEO)
About 2 kg of the air-dried plant were used. For the ex-
traction of the essential oil, the stems were thrown and
the rest of the plant (leaves and flowers) was subjected
to the hydrodistillation for 4 h by using Clevenger appar-
atus. The obtained oil was yellowish with characteristic
odor; it was then separated from the distillate and stored
in sealed glass vial at 4 °C until the moment of analysis.
The essential oil was obtained in a yield of 0.4% (w/w).
Gas Chromatography (GC) analysis
The GC analysis of AcEO was performed on an Agilent
5973 N GC-MS coupled to an Agilent 6890 gas chromato-
graph fitted with an injector at 250 °C (Splitless mode) and
equipped with an HP-5MS capillary column coated with
5% phenyl-methyl siloxane (30 m length × 0.25 mm internal
diameter × 0.25 μm of film thickness, Agilent 19091S-433).
The column pressure was set to 51.6 × 103 Pa. The oven
temperature was held at 40 °C for 2 min, and then
programmed to 250 °C at a rate of 8 °C/min. Helium was
used as the carrier gas at a flow rate of 1.1 ml/min. Diluted
sample in diethyl ether was manually injected.
Gas-Chromatography-Mass Spectrometry (GC-MS) analysis
The GC–MS analysis of AcEO was performed on an
Agilent 5973 N GC-MS coupled to an Agilent 6890 gas
chromatograph fitted with an injector at 250 °C (Splitless
mode) and equipped with an HP-5MS capillary column
coated with 5% phenyl-methylsiloxane (30 m length ×
0.25 mm internal diameter × 0.25 μm of film thickness,
Agilent 19091S-433). The column pressure was set to
51.6 × 103 Pa. The oven temperature was held at 40 °C
for 2 min, and then programmed to 250 °C at a rate of
8 °C/min. Helium was used as the carrier gas at a flow
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rate of 1.1 ml/min. The mass spectra (MS) were oper-
ated in electron impact mode (70 eV) with the electron
multiplier set at 1823.5 V, and the MS data were ac-
quired in scan mode. The peaks were quantified by cal-
culating the percentage of the peak area of each
component by comparison to the sum of the peaks of
other compounds. The identification of the components
was performed on the basis of chromatographic com-
parison of the recorded retention time with computed
mass-spectrum data libraries (Pal600K and Wiley275).
β-Carotene bleaching assay
The β-Carotene bleaching test of AcEO was determined
based on the standard procedure [41]. A volume of 1 ml
of chloroform solution of β-carotene (0.1 mg/ml) was
added to a round flask containing 20 mg of acid linoleic
and 200 mg of Tween 40. Chloroform was completely
removed at 40 °C under vacuum, and 50 ml of distilled
water was slowly added and vigorously shaken. Three
doses of AcEO and the reference standard Ascorbic acid
(0.1; 1 and 2 mg/ml) were dissolved in methanol. Ali-
quots (200 μl) of AcEO and ascorbic acid were added to
5 ml of β-carotene/linoleic acid emulsion. A control
preparation was obtained by adding 200 μl of methanol
to 5 ml of β-carotene/linoleic acid emulsion. Absorbance
of the preparations was measured at 490 nm before and
after 2 h of incubation in a water bath at 50 °C. All trials
were performed in triplicate. Antioxidative activity (AA






Wher Ac0 is the absorbance of the control respectively
measured before the incubation. As120 and Ac120 are the
absorbance of the test and the control respectively mea-
sured after 2 h of incubation.
DPPH radical scavenging assay
The DPPH free radical scavenging activity of the EOs
was evaluated as described by Senthilkumar et al. [42],
with slight modifications. A volume of 1 ml of 0.1 mM
of methanolic solution of the free radical 2,2-diphenyl-1-
picryl-hydrazyl (DPPH) was added to 1 ml of increased
doses of AcEO ranging from 0.1 mg/ml to 2 mg/ml
previously dissolved in methanol. A control sample
using methanol instead of AcEO was prepared. Ascorbic
acid dissolved in methanol (0.1–2 mg/ml) was used as
standard. The preparations were incubated for 30 min in
obscurity at room temperature, then after, absorbance
was measured at 517 nm. Pure methanol was used as
blank. Measurements were carried out in triplicate for
each experiment.
Antioxidant activity was calculated using the equation:




Where Ac is the absorbance of the control and As is
the absorbance of the sample.
Experimental animals
Wistar rats and albino mice were provided from the local
colonies of department of Biology (Faculty of Sciences,
Oujda-Morocco); they were maintained in standard condi-
tions, with a photoperiod of 12 h light and dark, and they
were allowed to free access of water and food. All animals
were cared for in compliance with the Guide for the Care
and Use of Laboratory Animals, published by the US
National Institutes of Health (NIH) [43].
Acute toxicity
Acute toxicity of AcEO was performed on the basis
of the protocols conducted in previous similar studies
[44, 45]. 25 albino mice were divided into five groups
of five animals each. After 18 h of fasting with free
access to water, the doses of 0.5, 1, 1.5 and 2 mg/kg
of AcEO were given orally to the mice, using a solu-
tion of gelatin 5% as vehicle. The control group was
fed with 0.5% gelatin solution. The use of gelatin as
an emulsifier is attributed to its non-toxic and non-
irritability qualities as carrier molecule [46], besides
its hydrophobic character that makes this macroprotein
preferably used in pharmaceutical application and food in-
dustry as natural emulsifier and stabilizer [47, 48]. Also,
gelatin is largely used as biodegradable macromolecule
largely used for encapsulation of essential oils, mainly uti-
lized in pharmaceutical and cosmetics to prevent eventual
decomposition, evaporation or oxidation of the volatile
oils [49]. Indeed, Sutaphanit and Chitprasert (2014)
demonstrated that there was no significant interaction be-
tween gelatin and basil essential oil, along the encapsula-
tion process [50]. General behavior and mortality were
observed permanently during the four hours succeeding
the dosing, and occasionally during the first 24 h. The
animals were monitored daily for any additional signs of
toxicity and weekly for changes in body weight. Dead
animals were sacrificed just after their death and the sur-
vived animals were sacrificed at the end of the experimen-
tation by overdose of anesthesia by ethylic ether, and the
organs were examined macroscopically for any toxico-
logical alterations. The stomach was longitudinally incised
by the greater curvature and ulceration or perforations of
gastric mucosa were observed. The liver and kidneys have
been weighted after been cleaned from connective tissues.
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Platelet aggregation assay
Wistar rats weighing 250–380 g were slightly anesthetized
with ether. Abdominal aorta was catheterized and blood
was collected in anti-coagulated tubes with a mixture of
acid citric (130 mM)-trisodium citrate (170 mM)-glucose
4% (9:1, v/v). Washed platelets were prepared according to
the experimental design reported by Gadi et al. [51]. A first
centrifugation of blood (230 x g/15 min) was made and
permitted to obtain a platelet rich plasma (PRP), which was
centrifuged a second time (400 x g/ 15 min) to obtain the
platelet pellet. The platelets were then washed once with
washing buffer (NaCl 137 mM, KCl 2.6 mM, NaHCO3,
12 mM, MgCl2 0.9 mM, glucose 5.5 mM, gelatin 0.25%,
pH 6.5), centrifuged for the last time (400 × g/ 15 min) and
suspended in the final buffer with the following compos-
ition (mM): NaCl 137, KCl 2.6, CaCl2 1.3, MgCl2 0.9, glu-
cose 5.5, Hepes 5, gelatin 0.25%, pH 7.4) in order to have a
final platelet concentration of 5 × 105 cells/mm3.
Platelet aggregation was performed using an aggreg-
ometer (Chrono-Log, Havertown, PA, USA). In a special
tube containing 400 μl of washed platelets at 37 °C with
continual stirring at 1000 rpm, the aggregation was stimu-
lated with aggregating agents, thrombin (0.1 U/ml) and
ADP (1 μM). For test studies, platelets were preincubated
with different concentrations of AcEO (0.1, 0.5 and 1 mg/
ml) for 1 min in the cuvette before the stimulation by the
aggregating agents cited above. In all experiments, the
platelet aggregation was then recorded during 5 min.
AcEO was dissolved in 0.5% DMSO. Control experiments
demonstrated that the concentrations of DMSO had no
significant effect on the aggregatory effect.
Determination of the mechanism underlying the
vasorelaxant activity of AcEO
The vascular tone was measured by referring to previ-
ously described procedure [52]. Wistar rats weighting
200-300 g were anesthetized with sodium pentobarbital
(0.1 ml/100 g body weight). The thoracic aorta was
quickly and gently removed, cleaned of adherent con-
nective tissue and cut into rings (3-4 mm in length).
Rings were gently introduced between two stainless-steel
hooks and placed in organ chamber (emka technologies,
Paris) containing 11 ml of Krebs solution gassed with
95% O2 and 5% CO2 and maintained at 37 °C and
pH 7.4. One hook was connected to an isometric force
transducer (emka technologies, Paris) and a tension of
1 g was applied to the vessels then they were allowed to
stabilize for 30 min. The composition of Krebs solution
was as follows (mmol/L): NaCl 119, KCl 4.7, CaCl2 2.6,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, and Glucose 11.
Endothelial integrity was monitored by the percentage of
relaxation evoked by carbachol (10−4 M) after a steady
contraction was reached with phenylephrine (10−6 M).
Rings with carbachol-induced relaxation less than 50%
were discarded. AcEO was dissolved in final concentration
of 0.5% DMSO. Control experiments showed that DMSO
at 0.5% had no significant effect on the vascular tone.
Vasorelaxant effect of AcEO on denuded aorta, and on
intact aorta preincubated with Atropine and
Calmidazolium
In endothelium-intact aorta (n = 6), steady tension was
evoked by Phen (1 μM), then, AcEO (10−4–10−1 mg/ml)
was cumulatively added to the Krebs solution. The contri-
bution of endothelium, muscarinic receptor and subsequent
Ca2+-CaM complex formation in the vasorelaxation-
induced effect was checked out by the application of
experiments described by Monteiro et al. [46]. Denuded
rings (n = 6) were obtained by gentile rubbing of the lumen
of aorta with a plier curved end, and the denudation was
verified by the absence of any degree of relaxation caused
by carbachol (10−4 M), then, AcEO (10-4–10-1 mg/ml) was
cumulatively added. In another set of experiments,
endothelium-intact rings were pre-incubated with the
muscarinic receptor antagonist atropine (1 μM; n = 6) and
Ca2+-Calmodulin binding to NOS blocker calmidazolium
chloride (10−3μM; n = 6) for 20 min prior the contraction
with Phen (1 μM), then, the cumulative concentration–re-
sponse curves of AcEO were constructed and compared
with those obtained with untreated rings.
Vasorelaxant effect of AcEO on aorta preincubated with
L-NAME, Hydroxycobalamin, ODQ and 8-RP-Br-PET-cGMP
The endothelium-dependent vasorelaxant pathway was
studied as described by Monteiro et al. [53]. Endothelium-
intact rings were pre-incubated with the NO synthase in-
hibitor, L-NAME (10−4 M; n = 6), the NO scavenger,
hydroxocobalamin (3.10−5 M; n = 6), the guanylyl cyclase
inhibitor, ODQ (10−5M; n = 6), and the competitive
cGMP-dependent protein kinase G (PKG) inhibitor, Rp-8-
Br-PET-cGMP (3.10−6 M; n = 6) for 20 min prior the
contraction with Phen (1 μM), then, the cumulative con-
centration–response curves of AcEO were constructed
and compared with those obtained with untreated rings.
Vasorelaxant effect of AcEO on aorta preincubated with
potassium channels blockers, TEA, 4-AP, BaCl2 and
Glybenclamide
The involvement of potassium channels in the vasore-
laxant effect was assessed following the experimental
procedure previously detailed, with some variations [54].
Endothelium-intact rings were incubated with the Ca2+-
activated potassium channels, TEA (10−2M; n = 6), the se-
lective voltage-activated potassium channel (Kv) blocker, 4-
AP (10−4M; n = 6), the selective inwardly-rectifying potas-
sium channel blocker, BaCl2 (10
−4M; n = 6), and the
selective ATP-sensitive potassium channel blocker, glyben-
clamide (10−5M; n = 6) for 20 min prior to contraction with
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Phen (1 μM), then, the cumulative concentration–response
curves of AcEO were constructed and compared with those
obtained with untreated rings.
Vasorelaxant effect of AcEO on aorta preincubated with
Indomethacin, Thapsigargin and Verapamil
Calcium channels and prostanoid mediated vasodilation was
studied following the protocol detailed by Li et al. [55].
Endothelium-intact rings were pre-incubated with the non-
selective cyclooxygenase inhibitor, indomethacin (10−5M;
n = 6), and to explore the role of calcium channels in the
vasorelaxant effect, endothelium-intact rings were incubated
with the Ca2+-channel type VOC, verapamil (10−5 M; n = 6)
and the endoplasmic reticulum Ca2+-ATPase (SERCA) in-
hibitor, thapsigargin (10−7 M; n = 6) for 20 min prior to con-
traction with phenylephrine (10−6 M), then, the cumulative
concentration–response curves of AcEO were constructed
and compared with those obtained with untreated rings.
Vasorelaxant effect of AcEO on aorta precontracted with
Phen (1 μM) and K+ (80 mM) and comparative
vasorelaxant effect of cumulative doses of ACEO and
Verapamil on K+ (80 mM)
To confirm the involvement of voltage operated, and /or re-
ceptor operated calcium channels, and the enhancement of
calcium release form internal stores in the vasodilator effect
of AcEO, two sets of experiments were carried out as de-
scribed by [56]. First, cumulative doses of the AcEO (0.1–
100 μg/ml) were added to aorta precontracted with both K+
(80 mM) and Phen (1 μM). In another set of experiments, a
comparative profile of the vasorelaxant effect of ACEO cu-
mulative doses (10−4–10−1 mg/ml) and verapamil (10−8-10−6
M) was challenged on the aorta precontracted by K+
(80 mM).
Statistical analysis
The data were expressed as the mean ± standard error of
mean (SEM). The results were analyzed using one-way
and two-way analysis of variance (ANOVA), followed by
Bonferroni’s as a post-test. A value of p < 0.05 was con-
sidered significant. The linear and nonlinear regression
tests have been used as well. The chemical structures
have been drawn by using the freeware version of the
software ACD/ChemSketch (Freeware) 14.01.
Results
Chemical analysis
Chemical analyses (GC and GC/MS) of AcEO allowed the
identification of 42 compounds. The chromatographic
profile of the essential oil is shown in (Fig. 1). The oil has
the spathulenol (10.19%) as main component, followed
by ß-eudesmol (4.05%), p-cymene (3.83%), δ-cadinene
(3.67%), ß-pinene (2.82%), caryophyllene oxide (2.30%) and
salvial-4(14)-en-1-one (2.51%). The compounds mentioned
in Fig. 1 were systematically found in all the samples. The
chemical structures of the major chemical components
found in AcEO are presented in (Fig. 2).
β-Carotene bleaching assay
The prevention of β-carotene bleaching with linoleic acid
was similarly effective for AcEO (AAmax% = 82.2% ± 12.7)
and the standard ascorbic acid (AA max % = 86.65% ± 6.45)
and the antioxidant effect of both tested substrates was
higher than 50% (Fig. 3a).
DPPH radical scavenging assay
The radical scavenging activity of AcEO against DPPH rad-
ical increased significantly in dose-dependent manner
(Fig. 3b); the EC50 values calculated from the graph was
EC50 = 690 μg/ml. However, the radical scavenging activity
attributed to ascorbic acid seems to be more important,
characterized by a linear and stable shape of the graph with
a maximum of 96.23% of the antioxidant effect (AA %
higher than 50%).
Acute toxicity
During the experiment, animals treated with AcEO at
2 g/kg, showed several signs of intoxication like: hyper-
activity succeeded by asthenia, tremors, convulsion and
irregular breathing, yet, all these signs disappeared after
the first 24 h. The same dose provoked minimal lethality
(one animal dead), marked by an intense ulceration of
gastric mucosa. However, no significant changes have
been observed in organs and body weights monitored
during 2 weeks succeeding AcEO injection.
Antiplatelet effect
AcEO (0.1, 0.5 and 1 mg/ml) added to washed platelets
inhibited aggregation triggered by thrombin (0.1 U/ml)
and ADP (1 μM). The dose 1 mg/ml showed a maximum
inhibitory effect of, respectively, 49.73% ± 9.54 (p < 0.01)
and 48.20% ± 8.49 (p < 0.05) on thrombin and ADP -
induced platelet aggregation. However the doses 0.1 mg/ml
and 0.5 mg/ml of AcEO have no significant effect on the
antiplatelet effect (Fig. 4).
Determination of the mechanism underlying the
vasorelaxant activity of AcEO
Vasorelaxant effect of AcEO on denuded aorta, and on
intact aorta preincubated with Atropine and Calmidazolium
AcEO (0.1–100 μg/ml) abolished the contraction in-
duced by phenylephrine on intact thoracic aorta, and
induced 95.97% ± 2.03 of vasorelaxation. The vasore-
laxant effect induced by AcEO on denuded aorta
(102.07% ± 3.01; p > 0.05), also, the pretreatment with
calmidazolium (97.07% ± 3.29; p > 0.05), blocker of cal-
cium-calmodulin binding to NO synthase, did not affect
the vasorelaxation induced by AcEO. However, the
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vasorelaxation provoked by AcEO on aorta precontracted
with phenylephrine has been partially inhibited, when
preincubated with the muscarinic receptor inhibitor, atropine
(85.69% ± 6.56; p < 0.05) (Fig. 5a).
Vasorelaxant effect of AcEO on aorta preincubated with
L-NAME, Hydroxycobalamin, ODQ and 8-RP-Br-PET-cGMP
No significant difference on the vasorelaxation effect of
AcEO (0.1–100 μg/ml) on phenylephrine precontracted
aorta have been observed in the presence of NO synthase
inhibitor; L-NAME (97.27% ± 2.82; p > 0.05), in the pres-
ence of NO scavenger; hydroxocobalamin (93.99% ± 2.32;
p > 0.05), and in the presence of guanylyl cyclase inhibitor;
ODQ (92.26% ± 3.91; p > 0.05). However, relative inhibi-
tory effect AcEO-induced vasorelaxation have been
observed in the presence of the competitive cGMP-
dependent protein kinase G (PKG) inhibitor; Rp-8-Br-
PET-cGMP (87.86% ± 4.28; p < 0.05) (Fig. 5b).
Fig. 1 GC-MS chromtogram of A. campestris L. essential oil (AcEO)
Fig. 2 Chemical structures of volatiles compounds of A. campestris L. essential oil (AcEO)
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Vasorelaxant effect of AcEO on aorta preincubated with
potassium channels blockers, TEA, 4-AP, BaCl2 and
Glybenclamide
Pretreatment of aorta with potassium channels blockers;
TEA (98.91% ± 3, 73; p > 0.05), 4-AP (98.05% ± 2.96;
p > 0.05), BaCl2 (103.52% ± 2.47; p > 0.05) and glybencla-
mide (99.55% ± 2.66; p > 0.05), showed no significant
changes in AcEO (0.1–100 μg/ml) induced-vasorelaxation
(Fig. 6a).
Vasorelaxant effect of AcEO on aorta preincubated with
Indomethacin, Thapsigargin and Verapamil
Pretreatment of aorta with cyclooxygenase inhibitor;
indomethacin (92.95% ± 2.73; p > 0.05) did not produce
any significant difference of vasorelaxation induced by
AcEO precontracted with phenylephrine. Therefore,
aorta preincubated with endoplasmic reticulum calcium-
ATPase inhibitor; thapsigargin (45.34% ± 6.58; p < 0.001),
and calcium channel type VOC blocker; verapamil
Fig. 3 Antioxidant effect of A.campestris L. essential oil (AcEO) and ascorbic acid on (a) the scavenging of 2, 2(diphenyl-1-picryhydrazyl (DPPH) radical
(b) the prevention of β-carotene bleaching and; Values are mean ± SEM, n = 3, and analyzed with linear regression test
Fig. 4 The originaltrcing and percentage of aggregation inhibition of 0.1, 0.5 and 1 mg/ml of A. campestris L. essential oil (AcEO) on thrombin (a) and
ADP (b) induced platelet aggregation. Values are mean ± SEM, n = 6, analysed with one way ANOVA followed by Bonferroni’s post-test; p* < 0.005 vs
control and ** < 0.01 vs control
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(48.12% ± 8.21; p < 0.001) produced a sub-maximum
inhibitory effect of vasorelaxation induced by AcEO
(0.1–100 μg/ml) (Figs. 6b and 7).
Vasorelaxant effect of AcEO on aorta precontracted with
Phen (1 μM) and K+ (80 mM) and comparative vasorelaxant
effect of cumulative doses of ACEO and Verapamil on K+
(80 mM)
As shown in Fig. 8, AcEO triggered a concentration-
dependent vasodilation against Phen (1 μM) and K+
(80 mM) induced vasocontractions, with respective EC50
value of 0.005 mg/ml (n = 6) and 0.019 mg/ml (n = 6). In
parallel, AcEO and verapamil administered in increasing
doses to the plateau of K+ (80 mM), showed a similar
vasorelaxant profile with respective Emax values of
(97,04% + 4,08; n = 6) and (94,97% + 3,35; n = 6) (Fig. 9).
Discussion
Many studies have reported the chemical composition of
essential oil of A. campestris L. growing in different
countries. However, this study represents the first report
about the essential oil of A. campestris L. (AcEO) exist-
ing in Morocco. As shown in Fig. 1, GC/MS analysis of
essential oil of A.campestris L. resulted on the determin-
ation of spathulenol (10.19%) as the most prominent
compound, followed by ß-eudesmol (4.05%), p-cymene
(3.83%), δ-cadinene (3.67%), and ß-pinene (2.82%).
These findings are consistent with our new published
paper, which confirmed the similar chemical profile of
A.campestris L. essential oil collected in the flowering
stage of the year 2014 [57]. By comparison to the litera-
ture data, our findings are partially in accordance with a
study conducted in Iran by Kazemi et al. [58], in which
the predominated components of essential oil obtained
Fig. 5 Concentration–response curves of the vasorelaxant effect of A. campestris L. (AcEO) on (a) isolated aorta pre-contracted with phenylephrine
10−6 M, on denuded aorta and on aorta pre-incubated with Atropine and Calmidazolium, (b) with L-NAME, Hydroxocobalamin, ODQ and 8-RP-Br-
PET-cGMP. Values are mean ± SEM, n = 6, and analyzed with two way ANOVA followed by Bonferroni’s post-test; * p < 0.05 vs control
Fig. 6 Concentration–response curves of the vasorelaxant effect of A. campestris L. (AcEO) on (a) isolated aorta pre-contracted with Phen 1 μM, and in the
presence of TEA, 4-AP, BaCl2 and Glibenclamide, and in the presence of (b) Thapsigargin, Verapamil and Indomethacin. Values are mean ± SEM, n= 6, and
analyzed with two way ANOVA followed by Bonferroni’s post-test; *** p< 0.001 vs control
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from the flowers, leaves and stems of A.campestris L. were
α-pinene (23–29.2%) and spathulenol (15.8–29.2%).
Another work revealed the existence of the major volatiles
spathulenol and β-pinene in essential oil of A. campestris
L. from Serbia [2]. Previous studies reported the existence
of two chemotypes of A. campestris L. essential oil
occurring in different localities; the most relevant
chemotype consists mainly in β-pinene alone or together
with α-pinene occurring mainly in Tunisia [14, 59–62],
Algeria [10, 63–65], and Southern Ural [66], while the
other chemotype was characterized by the volatiles:
tremetone and capillen, detected in essential oil of A.
campestris L. growing in Turkey [24]. Moreover, it is
known that the species A.campestris L. presents great
variability in its essential oil composition due to the exist-
ence of different subspecies from different localities. In
France, A.campestris subsp. glutinosa has the main terpenes:
γ-terpinene and capillene [27, 67], while, the same subspe-
cies from Italy presented the major compounds: β-pinene,
germacrene D and bicyclogermacrene [68]. Other studies
Fig. 7 Original tracing showing the vasorelaxant effect of A. campestris L. essential oil (AcEO) on isolated aorta pre-contracted with Phen 1 μM (a) and
in the presence of Verapamil (b) and Thapsigargin (c)
Fig. 8 The originaltrcing (a) and the concentration–response curves (b) of the vasorelaxant effect of A. campestris L. essential oil (AcEO) on Phen
(1 μM) and on K+ (80 mM)-induced contraction. Values are mean ± SEM, n = 6, and analyzed with non linear regression test
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reported that A.campestris subsp. campestris essential
oil from Lithuania and Poland possesses the main
components: caryophyllene oxide, Z-falcarinol, germa-
crene D, β-pinene, γ-curcumene, γ-humulene [69–72].
The oils of other subspecies, maritima from Portugal
and borealis from Italy were rich in β-pinene, cadin-
4-en-7-ol, caryophyllene oxide and α-pinene [73–75].
Taking into account all these data, the species A.
campestris L. can be segregated into many chemo-
types based on the variation of the essential oil com-
position, which may lead to consider the species
growing in the arid region of Eastern Morocco as a
new chemotype characterized by the spathulenol as
the major compound.
Antioxidant effect of AcEO evaluated on the scavenging
of DPPH radical (EC50 = 690 μg/ml) seems to be consider-
able, though, the absence of a dose-response effect with
both AcEO and ascorbic acid seems to be confusing.
Indeed, the DPPH test reproducibility is controversial,
since it is limited by its lack of specificity; the DPPH assay
is not a competitive reaction, because the purple color of
the DPPH radical can be easily lost via either hydrogen
atom transfer (HAT) or reduction through single elec-
tron transfer (SET). Otherwise, the steric accessibility
of DPPH radical represent the major limitation of this
test that confers a more accessibility of the small
molecules to the radical site and which may conse-
quently have a higher antioxidant effect. On the other
hand, a large brand of antioxidant compounds with
peroxyl radicals may react slowly or may even be
inert in reaction to DPPH which is a nitrogen radical
in the first place [76, 77]. All these artefacts may
interfere with the actual antioxidant effect of the
AcEO and the ascorbic acid used as reference, which
may blind their effective antioxidant effect and omit
the dose-response efficiency of both substrates. On
the other hand, the DPPH radical scavenging obtained
with AcEO seems to be very important when com-
pared to that observed with the essential oil obtained
from the aerial part (IC50 = 94500 μg/ml) [14] and
leaves (IC50 = 1874 μg/ml) of Tunisian A.campestris L.
[59]. However, the essential oil extracted from leaves
of A.campestris L. occurring in Algeria appears to
have more efficient antioxidative potential on DPPH
Fig. 9 The original tracing (a) and the concentration–response curves (b) of the vasorelaxant effect of A. campestris L. essential oil (AcEO) and
Verapamil on K+ (80 mM)-induced contraction. Values are mean ± SEM, n = 6, and analyzed with linear regression test
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radical (IC50 = 39 μg/ml) [17]. On the other hand,
AcEO prevented 82.2% of β-carotene bleaching with
lineolate substrate, which is in agreement with study
reported by Akrout et al. [14].
The oral acute toxicity of AcEO resulted on an LD50
value greater than 2 g/kg, body weight. The essential oil
caused a minimal lethality witnessed by one dead animal
in the group fed by 2 g/kg, body weight, and which was
marked with an intense perforations and ulcerations of
gastric mucosa that probably causes the death. Other-
wise, there were any adverse effects on the body weight
or the organs weights monitored during the 15 days of
the study. On the basis of the present data AcEO is con-
sidered as toxic at 2 g/kg due to gastric lesions induced.
Additional studies about the toxicity of A. campestris L.
are available, showing that the intraperitoneal adminis-
tration of aqueous extract to mice showed an earlier tox-
icity with an LD50 = 2.5 g/kg of body weight [39].
Furthermore, an acute toxicity test of the essential oil of
A.campestris L. on brine shrimp larvae (Artemia sp.) gave
the median lethality dose ranging from 15 to 20 μg/ml
[69]. Concerning the platelet aggregation induced by both
agonists thrombin (0.1 U/ml) and ADP (1 μM), AcEO was
able to reduce it about 50%; so it can be postulated that
this oil may interact with the site of action of ADP and
thrombin and hence interrupting their cellular signaling
and antagonizing the aggregation process. This results
seems to be very considerable, by reference to a previous
study conducted by our team, where the pharmaceutical
anti-aggregant reference acetylsalicylic acid (1 mg/ml) in-
duced a total inhibition of the aggregability caused by
thrombin but at a quite high dose (1 mg/ml), if compared
with our study when thrombin is tested at the dose
0.1 mg/ml [78]. It has been reported that platelet activa-
tion and aggregation are participating in the emergence of
hypertension in different ways [79]. Platelets activation in
hypertension can be explained by several mechanisms,
among which the auto-degranulation that leads to activa-
tion of platelets exposed to increased shear force as result
of high blood pressure [80]. Activated platelets released
endogenous mediators like ADP which is known as a
platelet aggregating agent that interact with two platelets
receptors: Gq-coupled P2Y1 that induces a transient rise
in free cytoplasmic calcium and Gi-coupled P2Y12 that
provoke inhibition of adenylyl cyclase. Both pathways are
necessary to elicit platelet aggregation [81]. Thrombin is a
another platelet agonist that enhance aggregation; in fact,
thrombin induced platelets activation via protease-
activated receptors (PARs) that has a protein Gq-
action, enhancing activation of phospholipase C
(PLCβ), which hydrolyzes phosphatidylinositol 4,5
bisphosphate (PIP2), that promote the production of
second messenger IP3, which contributes to the in-
crease in intracellular Ca2+ through mobilization from
internal stores and influx from the extracellular de-
partment. The increase in intracellular Ca2+ regulates
many events leading to platelet aggregation [81].
The vasorelaxant effect of AcEO is obvious, since it
succeeded to abolish the contraction triggered by
phenylephrine, and produced a complete relaxation of
aorta. Indeed, it is well evidenced that phenylephrine
stimulates vascular contractions by acting through
stimulation of α1 adrenergic receptors, which will pro-
voke the conversion of phosphatidylinositol to inositol 1,
4, 5-triphosphate, leading to the release of Ca2+ from the
intracellular stores [82]. In light of these finding, we
aimed to highlight the mechanism of action of this
vasorelaxant effect, by exploring many cellular signaling
mechanisms, including endothelium-dependent and in-
dependent pathways.
The endothelium is a highly specialized layer of luminal
blood vessel, playing a key role in the vasorelaxation, me-
diated mainly by the release of endothelium-derived vaso-
dilators, like nitric oxide (NO) and prostacyclin [83–86].
By reference to our data, AcEO vasorelaxant effect ap-
pears to be endothelium-independent, since the vascular
response persisted after removal of the endothelium. In
the endothelial cell, the signalling mechanism responsible
for muscarinic receptor-dependent NO production in-
volves Ca2+ and calmodulin-dependent activation of
eNOS [87]. Once produced, calcium/calmodulin complex
(Ca2+/CaM) enhance the dissociation of eNOS from cave-
olae, which become catalytically active and induces NO
production [88]. The NO, as released by endothelial cells,
increased cGMP levels in the smooth muscle, activated
PKG, and phosphorylated the same vascular smooth
muscle proteins, which induces a decrease in intracellular
calcium concentration and a subsequent vasorelaxation
[89]. To check up the involvement of this pathway in the
vasorelaxant action of AcEO, aorta was submitted to spe-
cific inhibitors and blockers of endothelium mediators
that triggered the vasorelaxant action like atropine (non-
selective antagonist muscarinic receptors), calmidazolium
(Ca2+-calmodulin binding to NOS blocker), L-NAME
(NOS inhibitor), hydroxocobalamin (NO scavenger),
ODQ (inhibitor of soluble guanylyl cyclase) and protein
kinase G (PKG) inhibitor (Rp-8-Br-PET-cGMPs). Even
though, the vasorelaxation was not affected in the
presence of these drugs, which confirm that endothelium
and specifically NO-GC-PKG pathway was not involved
in this effect.
Another pathway of vasorelaxation endothelium-
dependent has been studied; it’s about the COX prod-
uct: PGI2 which is recognized for its potential ability
to relax vascular smooth muscle [90] via activation of
second messenger cAMP [91]. Hence, the possible
role of PGI2 seems to be ruled out, because the
pretreatment of aorta with, indomethacin, the COX
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inhibitor, did not change the vasorelaxant effect in-
duced by AcEO.
In vascular smooth muscle cell membrane, the open-
ing of potassium channels (K+) enhance an increase in K
+ efflux, provoking membrane potential (Em) hyperpo-
larization and subsequent closure of voltage-activated
calcium (Ca2+) channels, causing a decrease of intracel-
lular Ca2+ mobilization followed by a vasodilation [92].
In our experiments, the treatment of aorta with potas-
sium channels blockers did not change the vasodilator
action induced by AcEO, which suggests that the ob-
served effect is potassium channel-independent. Besides
K+ channels, Ca2+ channels contribute to the relaxant
effect of resistant vessels. The Ca2+ influx into vascular
smooth muscle have two preponderant pathways: one is
an L-type Ca2+ channel and the other is a store-operated
Ca2+ channel (STOC). L-type calcium channels are the
main gate of Ca2+ mobilization from extracellular space
during cell excitation. The Ca2+ influx through L-type
Ca2+ channels is the determinant of intracellular calcium
level in the vascular smooth muscle and hence the key
parameter of contraction [93]. Hence, the calcium antag-
onism via L-type calcium channel is a recognized as a
mechanism of vasorelaxation [94]. A decrease in Ca2+
levels into sarcoplasmic reticulum (SR) triggers refilling
of cytoplasmic Ca2+ in the SR Ca2+ store through sarco/
endoplasmic reticulum Ca2+ ATPase (SERCA) pump
and decreasing Ca2+ influx from STOC, which conse-
quently decreases intracellular Ca2+ and enhance the
vasorelaxation [95]. We performed separate experiments
with the blockers of SERCA pump (thapsigargin) and L-
type calcium channels (verapamil). As result, we found
that AcEO-vasorelaxation induced was decreased by
50% with both drugs. In addition, AcEO inhibited KCL-
induced contraction, and subsequently reduced the Ca2
+-induced contraction in aortic rings exposed to KCl,
and this effect was similar to that observed with increas-
ing doses of verapamil, a known calcium channel
blocker and a vasorelaxant drug, which confirms that
AcEO acts by blocking the L-type calcium channels.
However, A.campestris L. oil also inhibited Phen-
induced contraction, suggesting that it attenuated Ca2+
influx through receptor-operated Ca2+ channels as well.
In the matter of fact, the antagonizing effect of verap-
amil and thapsigargin remains debatable, since a persistent
vasorelaxation of AcEO was maintained after the pretreat-
ment with both drugs. These results suggest that the
vasodilator effect of AcEO may involve the synergetic
contribution of both calcium channels; otherwise, AcEO
may act concomitantly, on both channels, by blocking
VOCC channels, and by activating the SERCA pump,
both mechanisms will together participate in an additive
and/or synergetic manner to decrease the intracellular
levels of calcium leading to a subsequent vasorelaxation.
Conclusion
Herein, we have shown that the chemical profile drawn
for essential oil of A. campestris L. growing in Eastern
Morocco reveal a new chemotype related to this region
and spathulenol was identified as the predominant
component of this oil. The pharmacological properties
attributed to AcEO, like antioxidant, antiplatelet and
vasorelaxant effects seem to be very interesting. The
present work provide, also, evidence about the signaling
mechanism of vasorelaxation induced by AcEO, showing
that essential oil acts via L-type calcium channels and
SERCA pumps to reduce intracellular calcium, and
consequently triggering a sustained vasodilation.
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